Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb randomized study of alvimopan for opioid-induced bowel dysfunction in chronic non-malignant pain
2004-001182-18Phase 2Completed
- Sponsor
- GSK
- Start
- Aug 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of alvimopan in opioid-induced bowel dysfunction (OIBD) (4 arms), sponsored by GSK. Primary endpoint: Change in weekly spontaneous bowel movement frequency (weeks 1-3). Started Aug 2004; status: completed.
02
Drugs
alvimopan
03
Conditions
opioid-induced bowel dysfunction (OIBD)
Beyond the preview
Go deeper on 2004-001182-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001182-18.